First Command Advisory Services Inc. Sells 409 Shares of Merck & Co., Inc. (NYSE:MRK)

First Command Advisory Services Inc. cut its stake in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,672 shares of the company’s stock after selling 409 shares during the quarter. First Command Advisory Services Inc.’s holdings in Merck & Co., Inc. were worth $944,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Kennedy Investment Group increased its holdings in shares of Merck & Co., Inc. by 16.0% during the fourth quarter. Kennedy Investment Group now owns 2,564 shares of the company’s stock valued at $280,000 after acquiring an additional 354 shares in the last quarter. Schear Investment Advisers LLC increased its holdings in Merck & Co., Inc. by 16.0% in the 4th quarter. Schear Investment Advisers LLC now owns 3,233 shares of the company’s stock worth $352,000 after buying an additional 445 shares in the last quarter. Constitution Capital LLC increased its holdings in Merck & Co., Inc. by 5.9% in the 4th quarter. Constitution Capital LLC now owns 3,600 shares of the company’s stock worth $392,000 after buying an additional 200 shares in the last quarter. Harbour Trust & Investment Management Co bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $599,000. Finally, Mosaic Family Wealth Partners LLC increased its holdings in Merck & Co., Inc. by 4.0% in the 4th quarter. Mosaic Family Wealth Partners LLC now owns 2,995 shares of the company’s stock worth $327,000 after buying an additional 116 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Stock Performance

Shares of MRK stock traded up $0.55 during trading hours on Friday, reaching $125.78. 8,404,345 shares of the company traded hands, compared to its average volume of 6,808,079. Merck & Co., Inc. has a 12-month low of $99.14 and a 12-month high of $133.10. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The company has a market cap of $318.60 billion, a P/E ratio of 898.43, a P/E/G ratio of 1.62 and a beta of 0.38. The firm has a 50-day moving average price of $126.18 and a 200 day moving average price of $115.00.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.12. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm had revenue of $14.63 billion for the quarter, compared to analysts’ expectations of $14.49 billion. During the same period in the previous year, the firm earned $1.62 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. As a group, sell-side analysts predict that Merck & Co., Inc. will post 8.57 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, April 5th. Investors of record on Friday, March 15th were paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.45%. The ex-dividend date was Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 2,200.00%.

Insider Activity at Merck & Co., Inc.

In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Steven Mizell sold 50,694 shares of Merck & Co., Inc. stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total transaction of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares of the company’s stock, valued at approximately $2,991,346.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now directly owns 19,569 shares in the company, valued at approximately $2,443,972.41. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

MRK has been the subject of several research analyst reports. StockNews.com upgraded Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Barclays lifted their price objective on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Finally, TheStreet cut Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $131.25.

Get Our Latest Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.